AbbVie Inc (ABBV)vsHaemonetics Corporation (HAE)
ABBV
AbbVie Inc
$288.84
-0.98%
HEALTHCARE · Cap: $521.11B
HAE
Haemonetics Corporation
$120.28
+0.12%
HEALTHCARE · Cap: $5.38B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 4783% more annual revenue ($66.01B vs $1.35B). ABBV leads profitability with a 15.7% profit margin vs 7.1%. ABBV appears more attractively valued with a PEG of 0.60. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
HAE
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-88.0%
Fair Value
$156.84
Current Price
$288.84
$132.00 premium
Margin of Safety
+34.3%
Fair Value
$87.57
Current Price
$120.28
$32.71 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Expensive relative to growth rate
2.9% earnings growth
Distress zone — elevated risk
7.1% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : HAE
HAE has a balanced fundamental profile.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : HAE
The primary concerns for HAE are PEG Ratio, EPS Growth, Altman Z-Score. A P/E of 57.2x leaves little room for execution misses.
Key Dynamics to Monitor
ABBV profiles as a mature stock while HAE is a value play — different risk/reward profiles.
HAE carries more volatility with a beta of 0.61 — expect wider price swings.
ABBV is growing revenue faster at 10.3% — sustainability is the question.
ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 50/100), backed by strong 15.7% margins and 10.3% revenue growth. HAE offers better value entry with a 34.3% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Haemonetics Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Haemonetics Corporation, a healthcare company, offers medical products and solutions. The company is headquartered in Boston, Massachusetts.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?